Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT01356550
A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)
- Conditions
- Anemia
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1288
- Registration Number
- NCT01356589
- Locations
- 🇬🇷
Ahepa Hospital; 1St Dept. of Medicine, Thessaloniki, Greece
🇬🇷Kyanous Stavros of Patras, Renal Disease Therapy Unit, Patra, Greece
🇬🇷General Hospital Tzanio ; Nephrology, Piraeus, Greece
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 39
- Registration Number
- NCT01353859
An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma
- Conditions
- Renal Cell Cancer
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT01351571
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 485
- Registration Number
- NCT01351415
- Locations
- 🇺🇸
University of Pennsylvania; Radiation Oncology, Philadelphia, Pennsylvania, United States
🇯🇵Miyagi Cancer Center; Respiratory Medicine, Miyagi, Japan
🇺🇸USA Mitchell Cancer Institute, Mobile, Alabama, United States
A Study on the Effect of Food on the Pharmacokinetics of RO5428029 in Healthy Volunteers
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT01345942
A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT01344863
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4459
- Registration Number
- NCT01344889
An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 118
- Registration Number
- NCT01343914
An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT01343901
- Locations
- 🇫🇷
Fondation Bergonie; Gastro-Enterologie, Bordeaux, France
🇫🇷Clinique De L Europe; Pmsi, Amiens, France
🇫🇷Clinique Esquirol Saint Hilaire, Agen, France